TÜBINGEN, Germany, June 13, 2017 /PRNewswire/ -- CureVac AG, a fully-integrated biotechnology company pioneering mRNA
Ingmar Hoerr, PhD, co-founder and CEO of CureVac, stated, "The expansion of our prophylactic vaccine IP portfolio in the USA and Europe is another important milestone for CureVac as we seek to rapidly advance our RNActive® Prophylactic Vaccine pipeline and progress towards bringing the first potent mRNA vaccine to the market. Momentum within the mRNA space continues to accelerate as the pharma and biotech industries recognize the enormous potential of mRNA-based prophylactic vaccines for infectious diseases, oncology and other therapeutic applications. In November 2013, we successfully treated the first healthy volunteer in a first-ever human clinical prophylactic vaccine study, which signaled an important milestone for innovation in the development of mRNA-based therapies. These new patents amplify CureVac's leadership position and highlight the strength of our mRNA vaccine product portfolio."
In total, CureVac holds a broad IP portfolio comprising more than 100 patent families covering different aspects of its mRNA platform enabling the use and production of mRNA across a wide range of treatment modalities and disease indications.
CureVac's new intellectual property includes:
About CureVac AGFounded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a leading company in the field of mRNA technology and was the first company to start clinical trials on mRNA based drugs. The biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.
The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.
Since its inception, strongly backed by SAP founder Dietmar Hopp's dievini CureVac has received approximately $370 million (€355 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment and construction of industrial scale production facilities.
For more information, please visit www.curevac.com
Verena Lauterbach, Senior Manager CommunicationsCureVac AG, Tübingen, GermanyT: +49 (0) 7071 9883 firstname.lastname@example.org
Andrew Mielach, Vice President Tiberend Strategic Advisors, New YorkT: +1 212 375 email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/curevac-extends-global-intellectual-property-estate-for-prophylactic-mrna-vaccines-300472876.html
SOURCE CureVac AG
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All